Basic Information
LncRNA/CircRNA Name | AFAP1-AS1 |
Synonyms | NA |
Region | GRCh38_4:7754090-7778928 |
Ensemble | ENSG00000272620 |
Refseq | NR_026892 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | colon cancer |
ICD-0-3 | C18 |
Methods | qPCR, Western blot, in vitro knockdown, etc. |
Sample | CC tissues, human CC cell lines SW480, SW620, HCT116 and HT-29 |
Expression Pattern | up-regulated |
Function Description | analyzed the lncRNA expression patterns in Gene Expression Omnibus (GEO) datasets and the Cancer Genome Atlas (TCGA) RNA-seq datasets, and found that the expression level of AFAP1-AS1 was significantly elevated in CC tissues. High levels of AFAP1-AS1 were associated with poor disease-free survival and overall survival in CC patients. In vitro experiments demonstrated that AFAP1-AS1 knockdown significantly inhibited the cell invasive and migration capability in CC cell line HT-29. AFAP1-AS1 knockdown also increased the expression of E-cadherin and ZO-1 while inhibited the expression of Vimentin, MMP9, ZEB1 and ?-catenin, suggesting that AFAP1-AS1 is involved in the epithelial-mesenchymal transition (EMT) process of CC. Further studies confirmed that AFAP1-AS1 knockdown also affected the actin-cytokeratin signaling pathway. Thus, AFAP1-AS1 might be a potential novel diagnostic marker and therapeutic target for CC. |
Pubmed ID | 30588252 |
Year | 2018 |
Title | High Expression of lncRNA AFAP1-AS1 Promotes the Progression of Colon Cancer and Predicts Poor Prognosis |
External Links
Links for AFAP1-AS1 | GenBank HGNC NONCODE |
Links for colon cancer | OMIM COSMIC |